开发和描述含有flurbiprofen固体分散物的热敏和生物粘合性眼科配方
Pınar Adısanoğlu1, Işık Özgüney1
1Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Ege, 35100 Bornova, İzmir, Türkiye.
Gels (Basel, Switzerland)
|April 26, 2024
概括
这项研究开发了用于眼科flurbiprofen输送的新型热敏,生物粘合 in situ凝系统. 使用固体分散的优化配方显示出长时间的眼睛停留和改善生物可用性的潜力.
科学领域:
- 制药和药物输送 制药和药物输送
- 眼科医生 眼科 眼科
- 材料科学 材料科学 材料科学
背景情况:
- 眼科药物输送面临着快速前角膜清除和生物可用性差的挑战.
- 在现场凝系统通过在灌注时形成凝储存提供了优势,而不是传统的眼滴.
- 佛尔比,非类固醇抗炎药物,需要有效的输送用于眼部应用.
研究的目的:
- 开发和表征热敏和生物粘合在位凝系统用于眼科flurbiprofen固体分散剂 (FB-SDs).
- 评估波洛克萨默混合物和生物粘合聚合物的对凝性质,质和药物释放的影响.
- 评估这些系统的潜力,以提高flurbiprofen的眼部生物可用性.
主要方法:
- 用Poloxamer 407.7的融化方法制备了弗卢比烯固体分散剂 (FB-SDs).
- 使用Poloxamer 407/188混合物和结合生物粘合性聚合物 (Carbopol 934P或碳素甲基纤维素) 开发了热敏 in situ凝配方.
- 特性包括溶解性,稳定性,凝性质,风湿学,纹理分析和体外药物释放动力学.
主要成果:
- FB-SDs显著增加了flurbiprofen的水溶性 (332倍).
- 使用Poloxamer 407/188 (15/26.5%) 的配方表现出适合的凝温度 (32-35°C).
- 增加生物粘合性聚合物度降低了凝温度/时间;Carbopol 934P增强了凝硬度,可压缩性和粘合性. 配方F2 (0.2% CP),F5 (0.2% CMC) 和F6 (0.4% CMC) 显示出有希望的释放特征.
结论:
- 在现场开发的凝系统有效地结合了flurbiprofen固体分散物,提高了溶解度.
- 波洛克萨默和生物粘合聚合物 (Carbopol 934P或碳甲基纤维素) 的组合创造了强大的眼科凝.
- 优化的配方 (F2,F5,F6) 有望延长眼睛的停留时间并改善flurbiprofen的生物可用性.
相关概念视频
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
133
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
133
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
202
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
202
01:28Biopharmaceutics and Pharmacokinetics: Overview
2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K
01:27Factors Influencing Drug Absorption: Drug Dissolution
478
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
478
01:22Factors Influencing Drug Absorption: Physicochemical Parameters
268
The physicochemical characteristics of drugs play a crucial role in formulating stable and bioavailable drug products. The solubility of a drug, governed by the varying pH along the GI tract and its dissociation constant (pKa), is pivotal in determining its ionization state and absorption rate. Notably, weak acids and bases remain unionized and are absorbed more rapidly.
Enhanced drug absorption can be achieved by reducing particle sizes and increasing surface areas, thereby facilitating...
Enhanced drug absorption can be achieved by reducing particle sizes and increasing surface areas, thereby facilitating...
268